UCSD

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH

Retrieved on: 
tisdag, maj 21, 2024
Proton, Principal, Bangladesh Technical Education Board, Patient, Pharmacokinetics, MASH, Liver, Liver disease, University, Doctor of Philosophy, Therapy, Armed Forces Medical College, SAN, MBA, UCSD, MD, NIDDK, Magnetic resonance, NAFLD, Magnetic resonance imaging, Division, Digestive, Safety, Kidney, University of California, Hepatology, NIH

SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has completed enrollment in the ALG-055009 Phase 2a HERALD study for metabolic dysfunction-associated steatohepatitis (MASH) with topline safety and efficacy data anticipated in early Q4 2024. The company also announced that Dr. Rohit Loomba will serve as Principal Investigator for the study.

Key Points: 
  • The company also announced that Dr. Rohit Loomba will serve as Principal Investigator for the study.
  • “Completing enrollment in our first Phase 2a trial is a tremendous accomplishment for the Aligos team,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
  • In addition, I’d like to welcome Dr. Rohit Loomba as our Principal Investigator for the HERALD study.
  • “The excellent potency and PK profile makes ALG-055009 a compelling potential treatment option for MASH patients.

Ecodrive Awarded $300,000+ in Seed Funding at San Diego Angel Conference VI, with Runner Up Achieve Clinics Securing a $100,000+ Investment

Retrieved on: 
fredag, maj 10, 2024
Green Technology, Environment, Other Philanthropy, Other Technology, Software, Finance, Start-Up, Socially Responsible Investing, Environmental Issues, Environmental Health, Fund Raising, Professional Services, Foundation, Philanthropy, Technology, Mobile, Wireless, University, Apps, Applications, Education, Mentorship, Gust, Patient, Organization, Business, JPMorgan Chase, Conference, SDSU, UCSD, Cancer, SDAC, EcoDrive, San Diego State University, Multimedia, Pillsbury Winthrop Shaw Pittman

San Diego Angel Conference (SDAC) at the University of San Diego (USD), a program in its sixth year that activates accredited angel investors and engages promising early-stage companies, today awarded two startups with angel funding for their potentially disruptive solutions.

Key Points: 
  • San Diego Angel Conference (SDAC) at the University of San Diego (USD), a program in its sixth year that activates accredited angel investors and engages promising early-stage companies, today awarded two startups with angel funding for their potentially disruptive solutions.
  • View the full release here: https://www.businesswire.com/news/home/20240510917247/en/
    Left to right: Ecodrive Co-Founders Blake Ruschman, Trevor Laudate, and Markus Rommel hold $300,000 investment check from the San Diego Angel Conference at the University of San Diego for their startup that makes sustainability accessible, transparent, and effective.
  • We are incredibly grateful to the San Diego Angel Conference fund for this investment, which will enable us to scale.
  • SDAC partners with 35+ organizations including USD , San Diego State University ( SDSU ), and University of California San Diego ( UCSD ), to drive deal flow and mentor startups.

Terns Pharmaceuticals Announces Leadership Changes

Retrieved on: 
onsdag, maj 8, 2024
San Diego State University, University, UCSD, SDSU, CDO, Research, Obesity, BioMarin Pharmaceutical, Regulatory affairs, Cell biology, Acute myeloid leukemia, Drug development, Therapy, Growth, Pharmaceutical industry

Mr. Harris will report to the CEO and oversee clinical operations, regulatory affairs, chemistry manufacturing and controls, quality assurance and project management.

Key Points: 
  • Mr. Harris will report to the CEO and oversee clinical operations, regulatory affairs, chemistry manufacturing and controls, quality assurance and project management.
  • “Erin has played a key role in the growth and development of Terns over the last five years and in my transition to CEO,” said Amy Burroughs, chief executive officer of Terns.
  • “I have worked with Scott for many years and value the deep and diverse expertise across all areas of drug development that he brings to the leadership team at Terns,” said Ms. Burroughs.
  • “I expect my established rapport with the Terns leadership will accelerate my integration into the team, as we work together to advance these important new medicines for the benefit of patients.”

Healthier Capital Founder and Former One Medical CEO Endorses Medeloop Amid Launch of New AI Research Agent

Retrieved on: 
måndag, maj 6, 2024
UnitedHealth Group, UCSD, EVP, Health, Research, Amazon, ART, Stanford University, UCSF, 1Life Healthcare, Optum, General partnership

Rubin's board appointment is complemented by an investment in Medeloop from Healthier Capital, the venture capital firm he founded to partner with technology-powered healthcare innovators.

Key Points: 
  • Rubin's board appointment is complemented by an investment in Medeloop from Healthier Capital, the venture capital firm he founded to partner with technology-powered healthcare innovators.
  • This announcement aligns with the debut of Medeloop's new AI Research Agent, which the team has named ART.
  • Building on its robust platform, Medeloop has launched ART, an autonomous research agent poised to transform clinical research workflows with minimal human oversight.
  • "We are thrilled to welcome Amir Dan Rubin from Healthier Capital to Medeloop's board of directors," said CEO, Rene Caissie at Medeloop.

Mercedes-Benz Research & Development North America Funds Educational Initiatives in AI and Automated Driving at Stanford and University of California San Diego

Retrieved on: 
torsdag, maj 2, 2024
Technology, Automotive, Science, General Automotive, Robotics, Vehicle Technology, Engineering, Research, Automotive Manufacturing, University, Manufacturing, Software, Education, Internet, EV, Electric Vehicles, Autonomous Driving, Vehicles, Artificial Intelligence, UCSD, Safety, AI, Innovation, Artificial intelligence, Development, History, Stanford University, Silicon, Mercedes-Benz, SAIL, Multimedia, AVL, Perception, Student, CES, UC

Mercedes-Benz Research & Development North America, Inc. (MBRDNA), a Silicon Valley-headquartered research and development subsidiary of Mercedes-Benz, has started new research collaborations with two universities: 1.

Key Points: 
  • Mercedes-Benz Research & Development North America, Inc. (MBRDNA), a Silicon Valley-headquartered research and development subsidiary of Mercedes-Benz, has started new research collaborations with two universities: 1.
  • Stanford University School of Engineering; and 2. the University of California San Diego’s Contextual Robotics Institute.
  • MBRDNA has earmarked a six-month funding initiative aimed at advancing the research of AI and its potential to elevate in-car passenger experience and autonomous driving.
  • Strengthening MBRDNA’s commitment to academic institutions is the newly expanded research scope with the Contextual Robotics Institute at the University of California San Diego Jacobs School of Engineering.

ThinkCERCA Partners with the University of California San Diego for a Foundational Reading Teacher Course

Retrieved on: 
torsdag, maj 2, 2024
Education, University, UCSD, Literacy, Adolescence, ThinkCERCA, ECO, Outreach, Language development, Division, Knowledge, Tutoring

CHICAGO, May 2, 2024 /PRNewswire/ -- ThinkCERCA, a recognized industry leader in literacy, is proud to partner with the University of California at San Diego to offer a practicum in Secondary Foundational Reading and Linguistics.

Key Points: 
  • CHICAGO, May 2, 2024 /PRNewswire/ -- ThinkCERCA, a recognized industry leader in literacy, is proud to partner with the University of California at San Diego to offer a practicum in Secondary Foundational Reading and Linguistics.
  • This course will equip teachers with the knowledge and the skills to utilize in their classroom as soon as the next day.
  • Teachers will receive three semester hours of post-baccalaureate credit for this 8-week/45-hour course from the University of California at San Diego.
  • "The Education and Community Outreach (ECO) department at the University of California, San Diego Extended Studies is proud to partner with ThinkCERCA to unveil a groundbreaking practicum in Secondary Foundational Reading and Linguistics.

CIRM Awards $11.8 Million Grant for Clinical Trial in High-Grade Glioma Including Glioblastoma Using DB107, a Novel DGM7™ Genetic Biomarker-Guided Gene Therapy

Retrieved on: 
tisdag, april 30, 2024
University of Southern California, Efficacy, University, UCSD, Radiation, Resection, Regenerative medicine, HGG, TMZ, Doctor of Philosophy, RRV, GBM, WGS, Glioblastoma, Artificial intelligence, Depression, CIRM, UCSF, USC, Intravenous therapy, Neoplasm, Clinical trial, Medicine, SHROOM3, Whole genome sequencing, SAN, Medical imaging

We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.

Key Points: 
  • We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.
  • DB107 consists of two components: DB107–RRV (vocimagene amiretrorepvec) as a prodrug activator gene therapy and DB107–FC (extended-release 5–fluorocytosine [5–FC]) as an oral prodrug.
  • Retrospective analysis of an earlier randomized clinical trial in patients with recurrent HGG suggested improved overall survival in DGM7–positive patients treated with DB107.
  • "We are excited to conduct this novel trial which will be investigating several new approaches for the first time in patients with newly–diagnosed high–grade glioma.

Anova to Manage Study of DB107 Following Newly Awarded $11.8M CIRM Grant

Retrieved on: 
onsdag, maj 1, 2024
Other Health, Software, Research, Pharmaceutical, Philanthropy, Oncology, Technology, Foundation, Science, Biotechnology, Other Science, Health, FDA, University, UCSD, BTRC, Regenerative medicine, HGG, University of California, Partnership, Doctor of Philosophy, CIRM, UCSF, Patient, Analysis of variance, SOC, Enterprise, USC, Neuro

Anova Enterprises, Inc. (Anova), a technology enabled CRO dedicated to accelerating promising treatments, has collaborated with University of California at San Francisco (UCSF), University of California at San Diego (UCSD), the University of Southern California (USC) and Denovo Biopharma to manage a newly awarded $11.8M California Institute for Regenerative Medicine (CIRM) grant to support the development of DB107 in patients with newly diagnosed high-grade glioma.

Key Points: 
  • Anova Enterprises, Inc. (Anova), a technology enabled CRO dedicated to accelerating promising treatments, has collaborated with University of California at San Francisco (UCSF), University of California at San Diego (UCSD), the University of Southern California (USC) and Denovo Biopharma to manage a newly awarded $11.8M California Institute for Regenerative Medicine (CIRM) grant to support the development of DB107 in patients with newly diagnosed high-grade glioma.
  • DGM7 has been shown to be associated with increased overall survival with treatment of recurrent HGG, via retrospective analysis.
  • Anova was approached to assist with the development of the product and was instrumental organizing leading neuro-scientists, developing the study plans, securing FDA approval, preparing the CIRM application, and securing the ultimate CIRM award.
  • The Phase 1/2a clinical trial is a multicenter, open-label study designed to confirm whether treatment DB107, when added to standard-of-care (SOC), provides clinical benefit to patients with newly diagnosed HGG when compared to historical performance.

Nexalin Technology CEO Provides Letter to Shareholders

Retrieved on: 
onsdag, april 10, 2024
FDA, Post-traumatic stress disorder, Trial of the century, Development, Policy, Privacy, Sleep, Journal, UCSD, HHS, IP, Government, Optimism, Traumatic brain injury, Architecture, Public sector, Safety, PTSD, Collection, Insomnia, Jesse Russell, Depression, Federation, Mental health, Anxiety, HALO, University, Concussion, Science, Patent, Patient, Physician, Letter, Pharmaceutical industry

We believe our technology holds tremendous potential, including treatment applications for large and underserved markets within the fields of insomnia, depression, and anxiety.

Key Points: 
  • We believe our technology holds tremendous potential, including treatment applications for large and underserved markets within the fields of insomnia, depression, and anxiety.
  • The broad potential of our technology is especially noteworthy given the growing number of patients seeking more effective non-pharmacological treatment options.
  • We view this as a significant breakthrough, as mTBI is a prevalent and often debilitating condition with limited treatment options.
  • The recent positive clinical results, growing market adoption, and continued innovation all point toward a bright future for Nexalin.

Are You Ready for EHR eSource in Clinical Trials? Lessons From the Field, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
onsdag, april 17, 2024
Openclinica, Organization, UCSD, Health informatics, EHR, MD, EDC, Medicine, Entrepreneurship, Health information management, Cal Collins, FACP, Division, Knowledge

TORONTO, April 17, 2024 /PRNewswire-PRWeb/ -- In this webinar, the expert panel will present and discuss their real-world experiences in electronic health records (EHR) to electronic data capture (EDC) eSource integration in large-scale clinical trials. The attendees will gain insights into the modalities and realities of eSource, its impact on trial speed and accuracy and how to assess and ensure site and stakeholder readiness.

Key Points: 
  • In this free webinar, learn from real-world trials to understand the practical implications, benefits and challenges of eSource integration.
  • The featured speakers will share essential criteria for evaluating readiness across technology, skills and training and data and standards mapping.
  • Attendees will also explore how scaling eSource impacts trial efficiency and accuracy, positioning organizations at the forefront of clinical research excellence.
  • This webinar will help attendees acquire knowledge and tools needed to embrace eSource integration with confidence.